Case Summary: Sindell v. Abbott Laboratories 1980

Background: DES and the Identification Problem

Between 1947 and 1971, pharmaceutical companies across the United States manufactured and marketed diethylstilbestrol (DES) — a synthetic estrogen — prescribed to pregnant women to prevent miscarriages and pregnancy complications. Approximately 200 manufacturers produced DES from an identical generic formula, selling it under dozens of brand names.

DES was later found to be entirely ineffective at preventing miscarriages. Worse, daughters born to women who took DES during pregnancy developed a rare and aggressive cancer — clear-cell adenocarcinoma of the vagina and cervix — at unusually high rates, typically manifesting a decade or more after birth.

When DES daughters began filing suit in the 1970s, they confronted an impossible evidentiary wall: because DES was chemically fungible (all pills identical), because brand names were rarely recorded, and because decades had passed, plaintiffs could not identify which of the ~200 manufacturers had made the specific pill their mother swallowed. Under traditional tort law, an inability to prove which defendant caused the harm meant the claim failed.

Key Facts

Detail
Court	Supreme Court of California
Citation	26 Cal.3d 588; 607 P.2d 924 (1980)
Decided	20 March 1980
Plaintiff	Judith Sindell (DES daughter; diagnosed with bladder cancer at 19)
Defendants	Abbott Laboratories, Eli Lilly, E.R. Squibb & Sons, and eight other DES manufacturers
Drug at issue	Diethylstilbestrol (DES), prescribed 1947–1971; FDA withdrew approval 1971
Core problem	Plaintiff could not identify which of ~200 manufacturers made the DES her mother took
Majority	Justice Stanley Mosk (4–1)
Dissent	Justice Frank Richardson
Doctrine created	Market share liability

Prior Theories and Why They Failed

Judith Sindell pleaded four theories of liability, each rejected by the trial court:

• Concert of action — required proof that defendants acted in concert toward a common tortious plan; parallel marketing of an identical drug was not enough.
• Alternative liability (Summers v. Tice, 1948) — required all tortfeasors to be before the court; with ~200 DES manufacturers, that was impossible.
• Enterprise / industry-wide liability — required proof of a unified safety standard enforced industry-wide; DES manufacturers had no such formal coordination.
• Negligence per se — failed on causation for the same identification reason.

The trial court sustained the defendants' demurrer and dismissed. The California Supreme Court granted review to consider whether any viable theory existed.

The Majority: Market Share Liability (Justice Mosk)

Justice Mosk, writing for a 4–1 majority, held that a plaintiff who cannot identify which DES manufacturer supplied the drug that injured her may nonetheless sue, provided she joins defendants who together represent a substantial share of the DES market at the relevant time.

How Market Share Liability Works

1. The plaintiff sues multiple DES manufacturers who collectively held a substantial portion of the market.
2. Each defendant may exculpate itself by proving it could not have manufactured the DES taken by the plaintiff's mother (e.g., it did not sell DES in that geographic market at that time, or its product was chemically distinct).
3. Defendants who cannot exculpate themselves are held liable in proportion to their market share — not jointly and severally liable for 100%.
4. If some defendants settle or are dismissed, the remaining defendants bear only their own proportionate share; there is no full-compensation guarantee.

Policy Rationale

The court weighed four considerations in favour of the new doctrine:

• Defendants caused the risk. Each manufacturer that marketed DES contributed to the pool of potential harm.
• Defendants are better positioned to bear the loss. Manufacturers can spread costs through insurance and pricing; individual plaintiffs cannot.
• Deterrence. Imposing proportionate liability gives manufacturers an incentive to test products rigorously and maintain records.
• Fairness across defendants. Proportionate allocation — rather than joint and several — prevents any one manufacturer from bearing costs disproportionate to its causal contribution.

The court acknowledged this was an innovation, but stressed that the doctrine of Summers v. Tice already showed that courts can shift the burden of proof on causation when all defendants were negligent and the plaintiff's inability to identify the specific wrongdoer was not the plaintiff's fault.

The Dissent: Justice Richardson

Justice Richardson dissented on both doctrinal and constitutional grounds:

• Causation deficit. Tort liability has always required proof that this defendant harmed this plaintiff. Market share liability allows recovery without that proof — it is, Richardson argued, liability by statistical association rather than by actual cause.
• Due process concern. Defendants are forced to pay damages for an injury they may not have caused. A manufacturer with a 20% market share is held liable in 20% of every DES case even if, in many of those cases, its pill was never ingested by the relevant plaintiff.
• Legislature's role. A change this radical to the foundations of tort law should come from the legislature, not the courts.

Richardson J's dissent has been influential: courts in most states ultimately sided with his reasoning when declining to adopt the doctrine.

Adoption, Modification, and Rejection by Other Courts

Jurisdiction	Case	Outcome
New York	Hymowitz v. Eli Lilly & Co., 73 N.Y.2d 487 (1989)	Adopted — but used a national market share; exculpation not allowed even if defendant proves it didn't sell locally
Washington	Martin v. Abbott Laboratories, 102 Wn.2d 581 (1984)	Adopted with modifications
Wisconsin	Collins v. Eli Lilly & Co., 116 Wis.2d 166 (1984)	Adopted a risk-contribution variant
Pennsylvania	Skipworth v. Lead Industries Ass'n, 690 A.2d 169 (1997)	Rejected — declined to extend to lead paint
Michigan, Ohio, Texas, Illinois, Georgia	Various	Rejected — held the doctrine incompatible with traditional causation

The majority of U.S. states have declined to adopt market share liability. California, New York, Washington, and Wisconsin represent the minority that accepted it, each with its own modifications.

Significance and Legacy

Sindell is foundational to modern products liability for three reasons:

1. It solved the fungibility problem. For the first time, courts had a workable framework for cases where a product's generic nature makes specific identification impossible.
2. It reconceived the causation requirement. Rather than requiring proof that defendant X caused plaintiff Y's specific harm, the court allowed probabilistic, market-level causation — a conceptual shift that influenced academic tort scholarship for decades.
3. It shaped pharmaceutical and industrial practice. Manufacturers improved labelling, batch-number recordkeeping, and adverse-event surveillance partly in response to the liability risk Sindell created.

The doctrine has been raised (with mixed results) in asbestos cases, lead-paint cases, and MTBE groundwater contamination litigation — wherever the identity of the specific tortfeasor is unknowable because many identical products were placed into commerce.